belizatinib

a dual anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK) inhibitor

Also Known As:

4-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-(4-(propan-2-ylcarbamoyl)cyclohexyl)benzimidazol-2-yl)benzamide; TSR-011

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Arkenau, Hendrik-Tobias: 1 article (01/2019)
2.	Bobilev, Dmitri: 1 article (01/2019)
3.	Chan, Jian: 1 article (01/2019)
4.	Dziadziuszko, Rafal: 1 article (01/2019)
5.	Hughes, Lorraine: 1 article (01/2019)
6.	Lin, Chia-Chi: 1 article (01/2019)
7.	Lu, Sharon: 1 article (01/2019)
8.	Mita, Monica: 1 article (01/2019)
9.	Sachdev, Jasgit: 1 article (01/2019)
10.	Su, Wu-Chou: 1 article (01/2019)

1.	Lymphoma (Lymphomas) 01/01/2019 - "A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas."
2.	Neoplasms (Cancer) 01/01/2019 - "Here, we report the safety, tolerability and recommended phase 2 dose (RP2D) of TSR-011 in patients with relapsed or refractory ALK- and TRK-positive advanced cancers. "